Home・Aandelen Lijst・Travere Therapeutics Inc

Travere Therapeutics Inc

Gesloten

52.13 0.5

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

51.92

Max

52.33

Belangrijke statistieken
By Trading Economics
Inkomsten	1.8M -35M
Verkoop	42M 170M
EPS	-0.37
Winstmarge	-20.519
Werknemers	497
EBITDA	-24M -33M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+45.64% upside

Dividenden
By Acuity
Volgende Winsten	29 okt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	250M 5.4B
Vorige openingsprijs	51.63
Vorige sluitingsprijs	52.13

Travere Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 okt 2026, 23:51 UTC

Canada's Housing Starts Data Set for Release Amidst Weak Employment Figures, Forecasting 230K Units and Cautious Market Sentiment.

10 okt 2026, 23:41 UTC

Market Awaits NY Empire State Manufacturing Index Release Amid Cautious Optimism and Broader Economic Concerns on October 15, 2026.

10 okt 2026, 23:41 UTC

Philadelphia Fed Manufacturing Index for October 2026 set to release with optimistic growth forecast amid inflation concerns and upcoming earnings reports.

10 okt 2026, 23:41 UTC

Core Producer Prices Expected to Rise 0.3% in September, Amid Cautious Market Sentiment and Inflation Concerns Ahead of Key Economic Reports

10 okt 2026, 23:41 UTC

US Producer Price Index Expected to Rise 0.5% Amidst Deteriorating Consumer Confidence and Inflation Concerns Ahead of October Release

10 okt 2026, 23:31 UTC

Australia's upcoming employment data release on October 15 is crucial, following a significant decline in full-time jobs and amid cautious economic sentiment influenced by global market fluctuations.

10 okt 2026, 23:31 UTC

Australia's Unemployment Rate Expected to Rise to 4.6% in September, Sparking Concerns Over Labor Market Stability Amid Global Economic Volatility

10 okt 2026, 23:31 UTC

Australia's Employment Change Report on October 15 Expected to Show Job Growth Amid Global Labor Market Concerns.

10 okt 2026, 23:21 UTC

US CPI Release on October 14 Sparks Caution Among Investors Amid Declining Consumer Sentiment and Inflation Concerns

10 okt 2026, 23:21 UTC

U.S. CPI data release on October 14 expected to show inflation rise to 3.6%, amid declining consumer confidence and fears of Federal Reserve tightening ahead of midterm elections.

10 okt 2026, 23:21 UTC

Core Inflation Rate Release on October 14, 2026, Expected to Rise by 0.2%, Influencing Federal Reserve Interest Rate Decisions Amidst Cautious Market Sentiment and Consumer Concerns Over Rising Costs.

10 okt 2026, 23:21 UTC

U.S. Inflation Rate Expected to Rise 0.6% in September Amid Consumer Confidence Decline and Geopolitical Tensions, Influencing Federal Reserve Policy Discussions

10 okt 2026, 23:21 UTC

Market Anticipates CPI Release Amid Rising Inflation Concerns and Mixed Investor Sentiment

10 okt 2026, 23:21 UTC

Core Inflation Rate for September 2026 Expected to Rise Slightly to 2.5%, Heightening Market Caution Amidst Rising Consumer Sentiment and Geopolitical Tensions.

10 okt 2026, 23:11 UTC

Brazil's Retail Sales Data Release on October 15 Expected to Reveal Consumer Spending Trends Amid Cautious Market Sentiment.

10 okt 2026, 23:01 UTC

Macro News

The Dow Jones Index (US) is trading roughly flat in after-market hours amid concerns over semiconductor stocks and heightened geopolitical tensions.

10 okt 2026, 22:51 UTC

Japan's Machinery Orders MoM data for August, set to release on October 14, is expected to show a modest 2.5% growth amid mixed manufacturing sentiment and concerns over softening demand.

10 okt 2026, 22:51 UTC

Australia's NAB Business Confidence report set for October 13 reveals cautious market sentiment amid declining confidence and rising costs, raising concerns over economic stability.

10 okt 2026, 22:51 UTC

RBA Meeting Minutes on October 13, 2026, Expected to Influence Interest Rate Decisions Amid Inflation Concerns and Global Economic Factors.

10 okt 2026, 22:51 UTC

The Nikkei 225 Index is roughly flat in after-market trading, holding steady since Friday's close amid positive sentiment ahead of upcoming corporate earnings reports.

10 okt 2026, 22:41 UTC

Singapore's Q3 2026 GDP Growth Rate Release on October 14 Sparks Cautious Optimism Amid Economic Recovery Signs and Mixed Asian Market Sentiments.

10 okt 2026, 22:41 UTC

U.S. 30-Year Mortgage Rates Hit 7.49% Amid Rising Treasury Yields and Inflation Concerns, Forecasting Continued Upward Pressure on Housing Market Demand

10 okt 2026, 22:31 UTC

Brazil's Central Bank to Release Key Interest Rate Insights Amid Rising Inflation on October 13, 2026.

10 okt 2026, 22:21 UTC

South Korea's Unemployment Rate Release on October 15 Expected to Reflect Labor Market Resilience Amid Global Economic Pressures.

10 okt 2026, 22:01 UTC

Spain's Consumer Confidence Index set for October 13 release amid cautious sentiment due to inflation and geopolitical tensions.

10 okt 2026, 21:31 UTC

Italy's Balance of Trade data set for October 16, with a forecasted €7.5 billion surplus amid cautious sentiment following disappointing industrial production figures.

10 okt 2026, 21:31 UTC

UK Retail Sales Monitor YoY for September 2026 Expected to Show Modest 0.7% Increase Amid Cautious Consumer Sentiment and Inflation Concerns

10 okt 2026, 20:41 UTC

India's Inflation Rate YoY Release on October 12, 2026, Expected to Reflect Ongoing Energy Price Pressures Amid Optimistic Market Sentiment.

10 okt 2026, 20:31 UTC

API Crude Oil Stock Change Report on October 14, 2026, to Reflect Inventory Fluctuations Amid Geopolitical Tensions and Market Caution Ahead of Key Inflation Data.

10 okt 2026, 20:31 UTC

Fed Governor Barkin's Upcoming Speech Sparks Cautious Market Sentiment Amid Inflation Concerns and Key Economic Data Releases.

Peer Vergelijking

Prijswijziging

Travere Therapeutics Inc Prognose

Koersdoel

By TipRanks

45.64% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 75.917 USD 45.64%

Hoogste 90 USD

Laagste 62 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Travere Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Travere Therapeutics Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.